Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

更正：对于活动性银屑病关节炎且既往对肿瘤坏死因子抑制剂反应不足或不耐受的患者，伊克珠单抗单独使用或与传统合成疾病修饰抗风湿药（cDMARDs）联合使用均有效。